While the market seems to be stabilizing (obviously a relative term in this environment), simply hoping for a continual steady move up is not a sound strategy.While people can argue buy-and-hold vs. other more active strategies, we believe that the recent volatility has caused enough pain that investors are now paying more attention and searching for more active ideas. So today, we offer five ideas from our stable of newsletters. Each newsletter has an array of ideas, but we will select five each week as a teaser to all the other great ideas you can get from all the different newsletters we offer. Action Alerts PLUS: Jim Cramer bought 100 shares of Abbott Laboratories ( ABT) at $45. Cramer said, "Abbott has been weak for the past few days on no new information. The chatter is that portfolio managers are taking profits in health care in general and Abbott specifically because it was the best-performing pharma/med-tech last year. Also, there are concerns about Abbott making an acquisition, soft Humira trends and Xience pricing. Abbott has been masterful at doing deals in the past, that's how it got Humira and Xience in the first place." (Jim Cramer, Action Alerts PLUS, April 3, 2009) Cramer's Action Alerts PLUS portfolio is actually up 1.27% for 2009, vs. a decline in the S&P 500 of about 13%. In the most recent Action Alerts PLUS, Jim had several other picks. Click here to check them out.
Biotech Select: Adam Feuerstein sold his position in Celgene ( CELG) at $40.40 in the Biotech Select portfolio. Adam said, "Celgene's first-quarter profit warning, announced Tuesday evening, suggests the company is not growing as quickly as expected. As a result, I don't believe the stock will recover significantly for a long time -- and certainly not to the point where I can eke out any gains from the current portfolio position. The stock is bouncing today after a steep selloff Wednesday, so I will use the opportunity to close out this position." (Adam Feuerstein, Biotech Select, March 29, 2009) Adam Feuerstein's Biotech Select portfolio was up a whopping 12.09% during the first quarter alone. Biotech Select had some other solid ideas recently. Click here to check them out.